Streamline Health® Reports Fiscal Third Quarter 2024 Financial Results, Accelerates Anticipated Adjusted EBITDA Breakeven Timeline
- Net loss of ($2.5 million) during the third quarter of fiscal 2024 compared to a net loss of ($11.9 million) during the third quarter of fiscal 2023
- Company reiterated $15.5 million implemented SaaS ARR adjusted EBITDA breakeven run rate expectation
- Company accelerated expectation for achievement of SaaS ARR adjusted EBITDA breakeven run rate to the first half of fiscal 2025
ATLANTA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the third quarter of fiscal 2024, which was the three-month period ended October 31, 2024, and the nine-month period ended October 31, 2024.
Fiscal Third Quarter and Nine-Months Ended October 31, 2024 GAAP Financial Results
The following financial results have been prepared in accordance with Generally Accepted Accounting Principles (“GAAP”).
Total revenue for the third quarter of fiscal 2024 was $4.4 million compared to $6.1 million during the third quarter of fiscal 2023. For the nine months ended October 31, 2024, revenue totaled $13.2 million compared to $17.2 million during the same period in fiscal 2023. The change in total revenue was attributable to previously announced client non-renewals offset by successful implementation of new SaaS contracts.
SaaS revenue for the third quarter of fiscal 2024 totaled $2.9 million, 66% of total revenue, compared to SaaS revenue of $3.9 million, 64% of total revenue during the third quarter of fiscal 2023. For the nine months ended October 31, 2024, SaaS revenue totaled $8.7 million, 66% of total revenue, compared to $10.6 million, 62% of total revenue, during the same period of fiscal 2023. As previously reported, the Company had a SaaS contract which did not renew at the end of its 2023 fiscal year.
Net loss for the third quarter of fiscal 2024 totaled ($2.5 million) compared to a net loss of ($11.9 million) during the third quarter of fiscal 2023. For the nine months ended October 31, 2024 net loss totaled ($8.0 million) compared to a net loss of ($17.3 million) during the 2023 period. The third quarter and first nine months of fiscal 2023 included $10.8 million of impairment expenses offset by a $1.2 million and $1.9 million gain, respectively, from valuation adjustments which did not recur during the same periods in fiscal 2024. Net loss during the third quarter and first nine months of fiscal 2024 reflected lower total revenues and higher interest expense offset by reductions in cost of sales, SG&A and R&D expense of $1.9 million and $5.3 million, respectively, primarily due to the Company’s strategic restructuring at the end of fiscal 2023.
Cash and cash equivalents as of October 31, 2024, were $0.8 million compared to $3.2 million as of January 31, 2024. The Company had no outstanding balance on its revolving credit facility as of October 31, 2024, compared to $1.5 million as of January 31, 2024. Subsequent to the end of the quarter, on November 13, 2024, the Company and its principal lender amended certain financial covenants related to the Company’s senior term loan and revolving line of credit, which are described in more detail in the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended October 31, 2024. On November 20, 2024, the Company received a $1.0 million draw from its revolving line of credit.
Fiscal Third Quarter and Nine Months Ended October 31, 2024 Non-GAAP Financial Results
Adjusted EBITDA for the third quarter of fiscal 2024 was a loss of ($0.3 million) compared to $0.4 million during the third quarter of fiscal 2023. Adjusted EBITDA for the nine months ended October 31, 2024, was a loss of ($1.3 million) compared to a loss of ($1.8 million) during the same period in fiscal 2023. The change in adjusted EBITDA reflects lower total revenue as a result of the previously announced client non-renewals, offset by significant cost savings achieved through the previously announced strategic restructuring.
As of October 31, 2024, the Company’s total Booked SaaS Annual Contract Value (“ACV”) was $14.1 million compared to $15.0 million as of January 31, 2024. $12.0 million of the Booked SaaS ACV was implemented as of October 31, 2024, compared to $11.1 million as of January 31, 2024.
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal.
The Company reiterated that it believes its adjusted EBITDA breakeven run rate is $15.5 million of implemented SaaS ARR and expects to achieve this run rate during the first half of fiscal 2025. Due to the continued unpredictability of timing related to the closing of new contracts, the Company has not provided more specific guidance related to the timing of bookings.
Management Commentary
“During the quarter we expanded existing relationships through our new eValuator quality module, completed implementation for key accounts, including our first enterprise clients and added new logo wins. The resulting momentum has led us to accelerate our expected Adjusted EBITDA breakeven timeline,” stated Ben Stilwill, President and Chief Executive Officer of the Company. “The Streamline team is focused on expanding our client footprint, maintaining a high caliber of client service, improving our solutions and progressing our financial goals and our mission to ensure our nation’s health systems are paid for all of the care they provide.”
Conference Call
The Company will conduct a conference call on Tuesday, December 17, 2024, at 9:00 AM ET to review results and provide a corporate update. Interested parties can access the call by joining the live webcast: . You can also join by phone by dialing 877-407-8291.
A replay of the conference call will be available from Tuesday, December 17, 2024 at 12:00 PM ET to Tuesday, December 24, 2024 at 12:00 PM ET by dialing 877-660-6853 or 201-612-7415 with conference ID 13750374. An online replay of the presentation will also be available for six months following the presentation in the Investor Relations section of the Streamline website, .
About Streamline
Streamline Health Solutions, Inc. (Nasdaq: STRM) enables healthcare organizations to proactively address revenue leakage and improve financial performance. We deliver integrated solutions, technology-enabled services and analytics that drive compliant revenue leading to improved financial performance across the enterprise. For more information, visit .
Non-GAAP Financial Measures
Streamline reports its financial results in accordance with U.S. generally accepted accounting principles (“GAAP”). Streamline’s management also evaluates and makes operating decisions using various other measures. One such measure is adjusted EBITDA, which is a non-GAAP financial measure. Streamline’s management believes that this measure provides useful supplemental information regarding the performance of Streamline’s business operations.
Streamline defines “adjusted EBITDA” as net earnings (loss) before net interest expense, income tax expense (benefit), depreciation, amortization, share-based compensation expense, valuation adjustments, restructuring charges, transaction related expenses and other expenses that do not relate to our core operations such as severance and impairment charges. A table reconciling this measure to “net loss,” to the extent relevant items were recognized in the periods covered, is included in this press release.
Booked SaaS ACV represents the annualized value of all executed SaaS contracts, including contracts that have not been fully implemented, as of the measurement date, assuming any contract that expires during the twelve months following the measurement date is renewed on its existing terms unless the Company has knowledge of the non-renewal. Booked SaaS ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with GAAP on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. Booked SaaS ACV is not intended to be a replacement for, or forecast of, revenue. There is no GAAP measure comparable to Booked SaaS ACV.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements made by Streamline Health Solutions, Inc. that are not historical facts are forward-looking statements that are subject to certain risks, uncertainties and important factors that could cause actual results to differ materially from those reflected in the forward-looking statements included herein. Forward-looking statements contained in this press release include, without limitation, statements regarding the Company’s growth prospects, anticipated bookings, recognition of revenue from contracts included in Booked SaaS ACV, achievement of a breakeven SaaS ARR run rate, anticipated cost savings from previously announced strategic restructuring, expected improved implementation timelines and lower expenses for our clients, industry trends and market growth, adjusted EBITDA, success of future products and related expectations and assumptions. These risks and uncertainties include, but are not limited to, the timing of contract negotiations and execution of contracts and the related timing of the revenue recognition related thereto, the potential cancellation of existing contracts or clients not completing projects included in the backlog and Booked SaaS ACV, the impact of competitive solutions and pricing, solution demand and market acceptance, new solution development and enhancement of current solutions, key strategic alliances with vendors and channel partners that resell the Company’s solutions, the ability of the Company to generate cash from operations, the availability of additional debt and equity financing to fund the Company’s ongoing operations, the ability of the Company to control costs, the effects of cost-containment measures implemented by the Company, availability of solutions from third party vendors, the healthcare regulatory environment, potential changes in legislation, regulation and government funding affecting the healthcare industry, healthcare information systems budgets, availability of healthcare information systems trained personnel for implementation of new systems, as well as maintenance of legacy systems, fluctuations in operating results, effects of critical accounting policies and judgments, changes in accounting policies or procedures as may be required by the Financial Accounting Standards Board or other similar entities, changes in economic, business and market conditions impacting the healthcare industry generally and the markets in which the Company operates and nationally, the Company’s ability to maintain compliance with the terms of its credit facilities, and other risks detailed from time to time in the Streamline Health Solutions, Inc. filings with the U. S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s analysis only as of the date hereof. The Company undertakes no obligation to publicly release the results of any revision to these forward-looking statements, which may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Company Contact
Jacob Goldberger
Vice President, Finance
303-887-9625
| STREAMLINE HEALTH SOLUTIONS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (rounded to the nearest thousand dollars, except share and per share information) | |||||||||||||||
| Three Months Ended October 31, | Nine Months Ended October 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenues: | |||||||||||||||
| Software as a service | $ | 2,933,000 | $ | 3,924,000 | $ | 8,734,000 | $ | 10,630,000 | |||||||
| Maintenance and support | 878,000 | 1,070,000 | 2,651,000 | 3,327,000 | |||||||||||
| Professional fees and licenses | 608,000 | 1,139,000 | 1,841,000 | 3,278,000 | |||||||||||
| Total revenues | 4,419,000 | 6,133,000 | 13,226,000 | 17,235,000 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of software as a service | 1,512,000 | 1,677,000 | 4,356,000 | 5,159,000 | |||||||||||
| Cost of maintenance and support | 42,000 | 129,000 | 127,000 | 250,000 | |||||||||||
| Cost of professional fees and licenses | 831,000 | 1,072,000 | 2,558,000 | 3,202,000 | |||||||||||
| Selling, general and administrative expense | 2,880,000 | 4,122,000 | 9,060,000 | 12,079,000 | |||||||||||
| Research and development | 1,134,000 | 1,304,000 | 3,569,000 | 4,310,000 | |||||||||||
| Impairment of goodwill | — | 9,813,000 | — | 9,813,000 | |||||||||||
| Impairment of long-lived assets | — | 963,000 | — | 963,000 | |||||||||||
| Total operating expenses | 6,399,000 | 19,080,000 | 19,670,000 | 35,776,000 | |||||||||||
| Operating loss | (1,980,000 | ) | (12,947,000 | ) | (6,444,000 | ) | (18,541,000 | ) | |||||||
| Other (expense) income: | |||||||||||||||
| Interest expense | (496,000 | ) | (266,000 | ) | (1,457,000 | ) | (781,000 | ) | |||||||
| Valuation adjustments | — | 1,182,000 | (115,000 | ) | 1,905,000 | ||||||||||
| Other | — | — | (2,000 | ) | 31,000 | ||||||||||
| Loss before income taxes | (2,476,000 | ) | (12,031,000 | ) | (8,018,000 | ) | (17,386,000 | ) | |||||||
| Tax benefit | — | 120,000 | — | 59,000 | |||||||||||
| Net loss | $ | (2,476,000 | ) | $ | (11,911,000 | ) | $ | (8,018,000 | ) | $ | (17,327,000 | ) | |||
| Basic and Diluted Earnings Per Share: | |||||||||||||||
| Net loss per common share – basic and diluted* | $ | (0.61 | ) | $ | (3.15 | ) | $ | (2.01 | ) | $ | (4.61 | ) | |||
| Weighted average number of common shares – basic and diluted* | 4,055,268 | 3,780,689 | 3,981,406 | 3,756,420 | |||||||||||
*The Company effected a 15-for-1 reverse stock split effective as of 12:01am Eastern Daylight Time on October 4, 2024, and the Company’s common stock began trading on a split adjusted-basis when the market opened on October 4,2024. Comparative periods have been adjusted to reflect the impact of the reverse stock split.
| STREAMLINE HEALTH SOLUTIONS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (rounded to the nearest thousand dollars, except share and per share information) | |||||||||
| October 31, 2024 | January 31, 2024 | ||||||||
| (Unaudited) | |||||||||
| ASSETS | |||||||||
| Current assets: | |||||||||
| Cash and cash equivalents | $ | 754,000 | $ | 3,190,000 | |||||
| Accounts receivable, net of allowance for credit losses of $59,000 and $86,000, respectively | 2,824,000 | 4,237,000 | |||||||
| Contract receivables | 1,248,000 | 780,000 | |||||||
| Prepaid and other current assets | 567,000 | 629,000 | |||||||
| Total current assets | 5,393,000 | 8,836,000 | |||||||
| Non-current assets: | |||||||||
| Property and equipment, net of accumulated amortization of $328,000 and $291,000 respectively | 52,000 | 88,000 | |||||||
| Capitalized software development costs, net of accumulated amortization of $9,368,000 and $7,960,000, respectively | 5,165,000 | 5,798,000 | |||||||
| Intangible assets, net of accumulated amortization of $5,246,000 and $4,019,000, respectively | 10,844,000 | 12,071,000 | |||||||
| Goodwill | 13,276,000 | 13,276,000 | |||||||
| Other | 1,236,000 | 1,666,000 | |||||||
| Total non-current assets | 30,573,000 | 32,899,000 | |||||||
| Total assets | $ | 35,966,000 | $ | 41,735,000 | |||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||
| Current liabilities: | |||||||||
| Accounts payable | $ | 1,610,000 | $ | 1,253,000 | |||||
| Accrued expenses | 1,518,000 | 2,023,000 | |||||||
| Current portion of term loan | 2,250,000 | 1,500,000 | |||||||
| Deferred revenues | 6,095,000 | 7,112,000 | |||||||
| Acquisition earnout liability | 377,000 | 1,794,000 | |||||||
| Total current liabilities | 11,850,000 | 13,682,000 | |||||||
| Non-current liabilities: | |||||||||
| Term loan, net of current portion and deferred financing costs | 5,883,000 | 7,566,000 | |||||||
| Line of credit | — | 1,500,000 | |||||||
| Notes payable, net of deferred financing costs | 4,129,000 | — | |||||||
| Deferred revenues, less current portion | 190,000 | 173,000 | |||||||
| Total non-current liabilities | 10,202,000 | 9,239,000 | |||||||
| Total liabilities | 22,052,000 | 22,921,000 | |||||||
| Commitments and contingencies | |||||||||
| Stockholders’ equity: | |||||||||
| Common stock, $0.01 par value per share, 85,000,000 shares authorized; 4,265,821 and 3,929,446 shares issued and outstanding, respectively | 43,000 | 590,000 | |||||||
| Additional paid in capital | 137,588,000 | 133,923,000 | |||||||
| Accumulated deficit | (123,717,000 | ) | (115,699,000 | ) | |||||
| Total stockholders’ equity | 13,914,000 | 18,814,000 | |||||||
| Total liabilities and stockholders’ equity | $ | 35,966,000 | $ | 41,735,000 | |||||
| STREAMLINE HEALTH SOLUTIONS, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (rounded to the nearest thousand dollars) | |||||||
| Nine Months Ended October 31, | |||||||
| 2024 | 2023 | ||||||
| Net loss | $ | (8,018,000 | ) | $ | (17,327,000 | ) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
| Depreciation and amortization | 3,594,000 | 3,264,000 | |||||
| Accrued interest expense - notes payable | 507,000 | — | |||||
| Valuation adjustments | 115,000 | (1,905,000 | ) | ||||
| Benefit for deferred income taxes | — | (104,000 | ) | ||||
| Share-based compensation expense | 1,483,000 | 1,626,000 | |||||
| Impairment of goodwill | — | 9,813,000 | |||||
| Impairment of long-lived assets | — | 963,000 | |||||
| Provision for credit losses | (58,000 | ) | — | ||||
| Changes in assets and liabilities: | |||||||
| Accounts and contract receivables | 1,003,000 | 4,299,000 | |||||
| Other assets | (116,000 | ) | (65,000 | ) | |||
| Accounts payable | 357,000 | 109,000 | |||||
| Accrued expenses and other liabilities | (505,000 | ) | (417,000 | ) | |||
| Deferred revenue | (1,000,000 | ) | (2,417,000 | ) | |||
| Net cash used in operating activities | (2,638,000 | ) | (2,161,000 | ) | |||
| Cash flows from investing activities: | |||||||
| Purchases of property and equipment | — | (47,000 | ) | ||||
| Capitalization of software development costs | (667,000 | ) | (1,562,000 | ) | |||
| Net cash used in investing activities | (667,000 | ) | (1,609,000 | ) | |||
| Cash flows from financing activities: | |||||||
| Repayment of bank term loan | (1,000,000 | ) | (500,000 | ) | |||
| Repayment of line of credit | (1,500,000 | ) | — | ||||
| Proceeds from line of credit | — | 500,000 | |||||
| Proceeds from issuance of common stock | 100,000 | — | |||||
| Proceeds from notes payable | 4,400,000 | — | |||||
| Payments of acquisition earnout liabilities | (886,000 | ) | — | ||||
| Payments related to repurchase of common shares to satisfy employee tax withholding | (77,000 | ) | (271,000 | ) | |||
| Payments for deferred financing costs | (168,000 | ) | — | ||||
| Other | — | — | |||||
| Net cash provided (used in) by financing activities | 869,000 | (271,000 | ) | ||||
| Net decrease in cash and cash equivalents | (2,436,000 | ) | (4,041,000 | ) | |||
| Cash and cash equivalents at beginning of period | 3,190,000 | 6,598,000 | |||||
| Cash and cash equivalents at end of period | $ | 754,000 | $ | 2,557,000 | |||
| STREAMLINE HEALTH SOLUTIONS, INC. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (Unaudited, rounded to the nearest thousand dollars) | |||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||
| In thousands, except per share data | October 31, 2024 | October 31, 2023 | October 31, 2024 | October 31, 2023 | |||||||||||
| Adjusted EBITDA Reconciliation | |||||||||||||||
| Net Loss | $ | (2,476 | ) | $ | (11,911 | ) | $ | (8,018 | ) | $ | (17,327 | ) | |||
| Interest expense | 496 | 266 | 1,457 | 781 | |||||||||||
| Tax benefit | — | (120 | ) | — | (59 | ) | |||||||||
| Depreciation and amortization | 1,187 | 1,105 | 3,260 | 3,186 | |||||||||||
| EBITDA | $ | (793 | ) | $ | (10,660 | ) | $ | (3,301 | ) | $ | (13,419 | ) | |||
| Share-based compensation expense | 451 | 517 | 1,483 | 1,626 | |||||||||||
| Impairment of goodwill | — | 9,813 | — | 9,813 | |||||||||||
| Impairment of long-lived assets | — | 963 | — | 963 | |||||||||||
| Non-cash valuation adjustments | — | (1,182 | ) | 115 | (1,905 | ) | |||||||||
| Acquisition-related costs, severance, and transaction-related bonuses | 16 | 213 | 372 | 389 | |||||||||||
| Restructuring charges | — | 749 | — | 749 | |||||||||||
| Other non-recurring charges | — | — | — | (33 | ) | ||||||||||
| Adjusted EBITDA | $ | (326 | ) | $ | 413 | $ | (1,331 | ) | $ | (1,817 | ) | ||||
Source: Streamline Health Solutions, Inc.
